Galectin Therapeutics Q3 EPS $(0.24) Misses $(0.16) Estimate;
Portfolio Pulse from Benzinga Newsdesk
Galectin Therapeutics (NASDAQ:GALT) reported a Q3 EPS loss of $(0.24), missing the consensus estimate of $(0.16) by 50%. This represents a 71.43% increase in losses compared to $(0.14) per share in the same quarter last year.
November 13, 2023 | 1:23 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Galectin Therapeutics reported a Q3 EPS loss of $(0.24), which was significantly below the analyst consensus estimate of $(0.16). The reported loss per share increased by 71.43% from the same period last year.
The reported earnings miss is likely to negatively impact investor sentiment in the short term, as the actual loss per share was significantly worse than expected. The substantial increase in losses year-over-year further exacerbates the negative outlook, suggesting potential underlying issues that could affect future performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100